Patients with pancreatic ductal adenocarcinoma (PDAC) usually have a dismal prognosis, and even after curative resection most patients will have disease relapse and ultimately die. Nonetheless, adjuvant chemotherapy has considerably improved the outcomes of patients who are able to undergo surgery. The PREOPANC trial provides some evidence supporting the use of neoadjuvant therapy for patients with borderline resectable PDACs but not, as claimed, for those with resectable tumours.

中文翻译：

---

新辅助治疗对可切除胰腺癌的作用仍不确定

胰腺导管腺癌（PDAC）患者的预后通常很差，即使在根治性切除后，大多数患者也会出现疾病复发并最终死亡。尽管如此，辅助化疗显着改善了能够接受手术的患者的预后。PREOPANC 试验提供了一些证据支持对临界可切除 PDAC 患者使用新辅助治疗，但如声称的那样，对于可切除肿瘤患者则不然。